• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Korea·Healthcare·009290.KS
Share

Kwang Dong Pharmaceutical Co., Ltd. Stocks

₩ 6410Last Updated 23.09.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Moderate

Recommendation

Hold

Market Cap

₩ 219.18M

₩ 6410
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Weak growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in Seoul, South Korea, in 1963, Kwang Dong Pharmaceutical Co., Ltd. functions as a diversified healthcare enterprise. The company is actively involved in the development and distribution of an extensive range of pharmaceutical products. This portfolio includes various over-the-counter (OTC) remedies addressing common ailments such as coughs and colds, eye care, liver conditions, mineral deficiencies, vitamin supplementation, circulatory health, and general wellness tonics. Complementing these are its prescription-only (ETC) medicines, which encompass treatments for a broad spectrum of medical needs, including diabetes, cardiovascular disorders, metabolic imbalances, digestive issues, immune system modulation, obesity, genitourinary and anal conditions, neurological and psychiatric disorders, pain and inflammation, infections, and anti-cancer therapies. Beyond pharmaceuticals, Kwang Dong offers health supplements and a diverse selection of beverages, ranging from general consumer drinks to functional and traditional health-focused options. The company also extends its operations to include the management of hospitals and facilitates widespread product distribution through various retail and wholesale channels, including discount stores, television home shopping, and online e-commerce platforms. Furthermore, Kwang Dong Pharmaceutical acts as a comprehensive MRO (Maintenance, Repair, and Operations) service provider, specializing in the procurement of raw materials, intermediate goods, and industrial consumables, with services extending to construction and international sourcing.

Company Valuation

Slightly undervalued
5/7

Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITDA, overpriced on P/F

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

23.09.2026 14:28

Is the small-cap rally coming to an end? 4 rules for picking stocks as the Fed raises rates

23.09.2026 14:02

Shares of Chinese AI developers fell following reports of an investigation into DeepSeek and Moonshot

23.09.2026 13:32

Apollo has restricted withdrawals from its private lending fund for the third consecutive time

23.09.2026 13:01

The crisis involving investment funds in Turkey is not over yet. What should investors keep an eye on?

23.09.2026 12:31

Oil is heading for its longest losing streak of the year. Traders' bets on a decline are at a peak.

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026